Determinación de la bioequivalencia del metronidazol, tabletas genérico, frente al innovador, comercializados en Ecuador mediante empleo de perfiles de disolución
Cargando...
Fecha
2023
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
La desinformación que existe en la población respecto a la efectividad que brindan los medicamentos genéricos para los tratamientos de todo tipo de patologías hace que se desconfíe de los mismos y se prefiera el consumo de medicamentos de marca que cuentan con una patente a pesar de ser fármacos que implican un gasto superior. El objetivo de la presente investigación es dar a conocer estos beneficios en el medicamento metronidazol tabletas de 500 mg mediante estudios de perfiles de disolución que van a comprobar la bioequivalencia entre el genérico y el innovador o de marca, estos análisis in vitro van a simular el comportamiento del fármaco dentro del organismo de la persona evaluando su capacidad de disolverse en determinados tiempos. Se determinó que el metronidazol de 500 mg genérico es bioequivalente al innovador ya que cumplió con los rangos de los factores F1 (0-15) y de F2 (50-100)
He misinformation that exists in the population regarding the effectiveness of generic drugs for the treatment of all types of pathologies leads to mistrust and a preference for the consumption of brand-name drugs that have a patent, despite the fact that they are drugs that imply a higher cost. The objective of this research is to show these benefits in the drug metronidazole 500 mg tablets through dissolution profile studies that will prove the bioequivalence between the generic and the innovator or brand name, these in vitro analyses will simulate the behavior of the drug inside the person's organism, evaluating its capacity to dissolve in certain times. It was determined that the generic metronidazole 500 mg is bioequivalent to the innovator since it complied with the ranges of factors F1 (0-15) and F2 (50-100).
He misinformation that exists in the population regarding the effectiveness of generic drugs for the treatment of all types of pathologies leads to mistrust and a preference for the consumption of brand-name drugs that have a patent, despite the fact that they are drugs that imply a higher cost. The objective of this research is to show these benefits in the drug metronidazole 500 mg tablets through dissolution profile studies that will prove the bioequivalence between the generic and the innovator or brand name, these in vitro analyses will simulate the behavior of the drug inside the person's organism, evaluating its capacity to dissolve in certain times. It was determined that the generic metronidazole 500 mg is bioequivalent to the innovator since it complied with the ranges of factors F1 (0-15) and F2 (50-100).
Descripción
Pdf
Palabras clave
METRONIDAZOL, BIOEQUIVALENCIA, PERFILES DE DISOLUCIÓN, MEDICAMENTOS GENÉRICOS